Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical combination comprising an antibacterial agent and an active substance selected from carveol, thymol, eugenol, borneol and carvacrol

A technology of thymol and therapeutic active substances, applied in the field of pharmaceutical compositions containing antibacterial drugs and active substances selected from carveol, thymol, eugenol, borneol, carvacrol, capable of solving shortening, immune Inhibition of difficult-to-treat issues such as life expectancy for patients

Active Publication Date: 2008-05-07
ADVANCED SCIENTIFICS INC
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] For example, in particular, immunosuppressed patients are becoming increasingly difficult to treat and their life expectancy is correspondingly shortened

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical combination comprising an antibacterial agent and an active substance selected from carveol, thymol, eugenol, borneol and carvacrol

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0056] Example 1: Treatment of different strain

[0057] In vitro test: determination of the minimum bactericidal concentration (MBC) against different strains

[0058] Experiments were performed with several Gram-negative and Gram-positive strains, which were isolated in a hospital setting and had different sensitivities. The antibiotic used is amoxicillin, which is one of the most effective and widely used antibiotics.

[0059] The antibacterial pharmaceutical composition according to the present invention is prepared by mixing different concentrations of amoxicillin and carveol at a sub-inhibitory concentration of 0.3 g / l solution or excipient (equivalent to 0.3 mg / ml). The lowest concentration of amoxicillin to produce a bactericidal effect in combination with 0.3 mg / ml carveol was determined. In each case, antibiotic activity was determined with amoxicillin alone, or with carveol alone, or with a composition of the invention.

[0060] Table 1 gives the results of th...

example 2

[0066] in vivo test

[0067] Groups of 10 mice were experimentally infected by intraperitoneal injection of 1,000,000 cells (colony forming units) of amoxicillin-resistant Klebsiella pneumoniae.

[0068] The first group consisted of control mice, which were infected and not treated.

[0069] The second group consisted of infected mice which were treated by gavage with amoxicillin alone at a dose of 10 mg / kg body weight / day 24 hours after their infection.

[0070] The third group consisted of infected mice which were treated with carveol alone at a dose of 120 mg / kg body weight / day by means of gavage 24 hours after their infection.

[0071] The fourth group consisted of infected mice, 24 hours after their infection, with the aid of gavage and with a dose of 2 mg / kg body weight / day of amoxicillin and 120 mg / kg body weight / day of carveol with the drug of the invention Infected mice were treated with the composition (AMOX-P).

[0072] Survival was measured over time. The res...

example 3

[0079] Example 3: Treatment of different strains with carveol-enhanced amoxicillin (Ampi-P)

[0080] Experiments were performed with several drug-resistant strains isolated in hospital settings. The antibiotic used was ampicillin from the beta-lactam class, which is one of the most widely used antibiotics. The antibiotic pharmaceutical composition according to the present invention is prepared by mixing different concentrations of ampicillin and sub-inhibitory concentrations of carveol in 0.3 g / l solution or excipient. This pharmaceutical composition of the present invention is called Ampi-P, standing for enhanced ampicillin. In each case, antibiotic activity was determined with ampicillin alone, or with carveol alone, or with a composition of the invention.

[0081] Table 2 presents the results of the static tests used to determine the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) in μg / ml.

[0082] Table 2

[0083] Bacteri...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical composition comprising at least one first active therapeutic substance selected among carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, as well as isomers, derivatives and mixtures thereof, and comprising at least one second active therapeutic substance that is an antibiotic. The invention is for use in the field of pharmaceutics.

Description

technical field [0001] The invention relates to a pharmaceutical composition comprising two therapeutically active substances, one of which exerts a synergistic effect on the other, and to the use of the composition. Background technique [0002] It is known that the efficacy of a therapeutic agent depends on the dose used, which in the case of partial resistance makes it necessary to increase the dose of the therapeutic agent in order to obtain the desired efficacy. Such dose increases lead to problems of adverse side effects and acute or chronic toxicity, which can significantly complicate the treatment of patients. [0003] Said partial drug resistance can be transformed into full drug resistance. In this case, increasing the dose no longer had any beneficial therapeutic effect, only toxic effects were observed. In such cases, treatment includes altering the therapeutic agent. [0004] This chain of events can repeat itself and lead to the most severe case: complete re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P31/04A61K45/06A61K31/045A61K31/05A61K31/43
CPCA61K31/05A61K45/06A61K31/43A61K31/045A61P31/00A61P31/04A61P43/00A61K2300/00
Inventor 阿德南·雷梅尔
Owner ADVANCED SCIENTIFICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com